Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Evaluation of Nivolumab in Adjuvant Esophageal Carcinoma/Gastroesophageal Junction Carcinoma: A Non-interventional Study

NCT05780736 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT05780736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05780736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Evaluation of Nivolumab in Adjuvant Esophageal Carcinoma/Gastroesophageal Junction Carcinoma: A Non-interventional Study
Lead sponsor
Bristol-Myers Squibb
Phase
Observational
Overall status
Terminated
Start date
August 4, 2023
Completion date
August 23, 2024
Enrollment
33 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal carcinoma, gastroesophageal junction carcinoma